January 2015
Biotech Business;Jan2015, Vol. 28 Issue 1, p2
Trade Publication
The article reports that biotechnology company Phosphagenics Ltd. has earned ethics approval for the commencement of proof of concept Phase 2 trial in Australia for its TPM/Oxycodone patch. Topics discussed include the trial's goal of determining the effectiveness of the patch for lessening the pain of post-herpetic neuralgia (PHN) patients and the provision of orphan drug status to PHN drugs. The ability of the patch to deliver oxycodone and act on inflamed tissue in a rat model is mentioned.


Related Articles

  • Comparison of the efficacy and safety of pregabalin for postherpetic neuralgia in Chinese and international patients. Parsons, Bruce; Pan, Xiaoping; Xie, Li; Chen, Yuxuan; Ortiz, Marie; Whalen, Ed // Journal of Pain Research;Sep2018, Vol. 11, p1699 

    Purpose: Pregabalin is indicated for postherpetic neuralgia (PHN) in multiple countries, including China. This analysis compared pregabalin efficacy and safety in Chinese and international patients with PHN. Patients and methods: Data from Chinese and international randomized, double-blind,...

  • OTHER NEWS TO NOTE.  // BioWorld International;5/30/2007, Vol. 12 Issue 22, p2 

    The article presents news briefs in biotechnology industry as of May 30, 2007. ACS Biomarker BV and BG Medicine entered an agreement granting BG rights to develop and commercialize a biomarker-based molecular diagnostic test. Ark Therapeutics Group plc was given clearance by the U.S. Recombinant...

  • Phosphagenics working on topical opioid patch.  // Australian Life Scientist;Mar/Apr2013, Vol. 10 Issue 2, p6 

    The article informs that Phosphagenics Ltd. has included an oxycodone-based patch designed for local pain relief in its pain patch portfolio and is also planning to start clinical trials of a similar version of the patch in the third quarter.

  • The effect and safety of ozone autohemotherapy combined with pharmacological therapy in postherpetic neuralgia. Hu, Bin; Zheng, Jie; Liu, Qing; Yang, Yunkuan; Zhang, Ying // Journal of Pain Research;Aug2018, Vol. 11, p1637 

    No abstract available.

  • Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years. Ceci, A.; Felisi, M.; Baiardi, P.; Bonifazi, F.; Catapano, M.; Giaquinto, C.; Nicolosi, A.; Sturkenboom, M.; Neubert, A.; Wong, I. // European Journal of Clinical Pharmacology;Nov2006, Vol. 62 Issue 11, p947 

    The 1995–2005 balance of EMEA activities in the field of paediatric medicines was evaluated, taking into account the number both of drugs authorised for children and paediatric studies supporting the Marketing Authorisation (MA). Data on drugs authorised by EMEA were extracted from EPARs...

  • Phase III.  // Applied Clinical Trials;Jul2005, Vol. 14 Issue 7, p14 

    Provides information related to latest phase three clinical trials. Initiation of a trial of tilarginine acetate for injection of cardiogenic shock by Arginox Pharmaceuticals; Efficacy of Takeda Pharmaceuticals Inc.'s ramelteon in reducing insomnia in elderly patients; Approval of Virulizin,...

  • Despite surge in orphan drug designations, approvals still lag. Heger, Monica // Nature Medicine;Mar2011, Vol. 17 Issue 3, p236 

    The article offers information on the orphan drug designation increase and its slow rate of approval by the U.S. Food and Drug Administration (FDA). It says that the steady increase in orphan drug designations for treatments of rare diseases in the last 10 years was due to the Orphan Drug Act of...

  • Chemokine bone cancer drug granted orphan drug designation.  // PharmaWatch: Biotechnology;Sep2005, Vol. 4 Issue 9, p12 

    The article reports that the U.S. Food and Drug Administration has granted orphan-drug designation to Chemokine Therapeutics Corp.'s drug, CTCE-9908, for the treatment of osteogenic sarcoma, a rare bone cancer that occurs in children and young adults. CTCE-9908 could potentially inhibit the...

  • CTI files for European orphan drug designation of lymphoma drug.  // PharmaWatch: Cancer;Nov2009, Vol. 8 Issue 11, p18 

    The article announces that an orphan drug designation for pixantrone for the treatment of non-Hodgkin's lymphoma is applied by Cell Therapeutics Inc. (CIT). It is noted that a 10-year market exclusivity in Europe will be granted if a marketing authorization application (MAA) is approved. It is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics